Implementation science: accelerating the pharma pipeline to its full potential

Geest, Sabina De; Thys, Alexander; Zullig, Leah L.

doi:10.2217/cer-2022-0152

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one sense, this is not surprising given that the post-marketing period is the phase in which implementation challenges related to uptake, adoption and sustainment are most publicly apparent. On the other hand, IS research is valuable in the pre-approval period as well [ 16 , 57 , 58 ]. In particular, it can reduce the time from drug discovery to use in clinical care, can inform product sponsors about potential barriers to uptake and adoption of their new product, and also allow for the identification of strategies to address them [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

The use of implementation science theories, models, and frameworks in implementation research for medicinal products: A scoping review

Smith,

Gaglio,

Anatchkova

2024

Health Res Policy Sys

View full text Add to dashboard Cite

Background The uptake, adoption and integration of new medicines and treatment regimens within healthcare delivery can take a decade or more. Increasingly, implementation science (IS) research is being used to bridge this gap between the availability of new therapeutic evidence and its actual application in clinical practice. Little is known, however, about the quality of IS research in this area, including the degree to which theories, models and frameworks (TMFs) are being used. The objective of this study was to conduct a scoping review of the use of TMFs in implementation research involving medicinal products. Methods A search was conducted for English language abstracts and manuscripts describing the application of TMFs in IS studies for medicinal products. Eligible publications were those published between 1 January 1974 and 12 December 2022. All records were screened at the title and abstract stage; included full-text papers were abstracted using data extraction tables designed for the study. Study quality was appraised using the Implementation Research Development Tool. Results The initial scoping search identified 2697 publications, of which 9 were ultimately eligible for inclusion in the review. Most studies were published after 2020 and varied in their objectives, design and therapeutic area. Most studies had sample sizes of fewer than 50 participants, and all focused on the post-marketing phase of drug development. The TMF most frequently used was the Consolidated Framework for Implementation Research (CFIR). Although most studies applied all TMF domains, TMF use was limited to instrument development and/or qualitative analysis. Quality appraisals indicated the need for engaging patients and other stakeholders in the implementation research, reporting on the cost of implementation strategies, and evaluating the unintended consequences of implementation efforts. Conclusions We found that few IS studies involving medicinal products reported using TMFs. Those that did encompassed a wide variety of therapeutic indications and medicinal products; all were in the post-marketing phase and involved limited application of the TMFs. Researchers should consider conducting IS in earlier phases of drug development and integrating the TMFs throughout the research process. More consistent and in-depth use of TMFs may help advance research in this area.

show abstract

Section: Discussionmentioning

confidence: 99%

The use of implementation science theories, models, and frameworks in implementation research for medicinal products: A scoping review

Smith,

Gaglio,

Anatchkova

2024

Health Res Policy Sys

View full text Add to dashboard Cite

show abstract

“…In one sense, this is not surprising given that the post-marketing period is the phase in which implementation challenges related to uptake, adoption, and sustainment are most publicly apparent. On the other hand, IS research is arguably as, if not more, valuable in the pre-approval period as well [16,57,58]. In particular, it can reduce the time from drug discovery to use in clinical care, can inform product sponsors about potential barriers to uptake and adoption of their new product, and also allow for the identi cation of strategies to address them [16].…”

Section: Discussionmentioning

confidence: 99%

The use of implementation science theories, models, and frameworks in implementation research for medicinal products: a scoping review

Smith,

Gaglio,

Anatchkova

2023

Preprint

View full text Add to dashboard Cite

Background: The uptake, adoption, and integration of new medicines and treatment regimens within healthcare delivery can take a decade or more. Increasingly, implementation science (IS) research is being used to bridge this gap between the availability of new therapeutic evidence and its actual application in clinical practice. Little is known, however, about the quality of IS research in this area, including the degree to which theories, models, and frameworks (TMFs) are being used. The objective of this study was to conduct a scoping review of the use of TMFs in implementation research involving medicinal products. Methods: A search was conducted for English language abstracts and manuscripts describing the application of TMFs in IS studies for medicinal products. Eligible publications were those published between January 1, 1974, and December 12, 2022. All records were screened at the title and abstract stage; included full-text papers were abstracted using data extraction tables designed for the study. Study quality was appraised using the Implementation Research Development Tool. Results: The initial scoping search identified 2,697 publications, of which nine were ultimately eligible for inclusion in the review. Most studies were published after 2020 and varied in their objectives, design, and therapeutic area. Most studies had sample sizes of fewer than 50 participants, and all focused on the post-marketing phase of drug development. The TMF most frequently used was the Consolidated Framework for Implementation Research (CFIR). Although most studies applied all TMF domains, TMF use was limited to instrument development and/or qualitative analysis. Quality appraisals indicated the need for engaging patients and other stakeholders in the implementation research, reporting on the cost of implementation strategies, and evaluating the unintended consequences of implementation efforts. Conclusions: We found that few IS studies involving medicinal products reported using TMFs. Those that did encompassed a wide variety of therapeutic indications and medicinal products; all were in the post-marketing phase and involved limited application of the TMF. Researchers should consider conducting IS in earlier phases of drug development and integrate the TMF throughout the research process. More consistent and in-depth use of TMFs may help advance research in this area.

show abstract

Implementation science: accelerating the pharma pipeline to its full potential

Cited by 2 publications

References 14 publications

The use of implementation science theories, models, and frameworks in implementation research for medicinal products: A scoping review

The use of implementation science theories, models, and frameworks in implementation research for medicinal products: A scoping review

The use of implementation science theories, models, and frameworks in implementation research for medicinal products: a scoping review

Contact Info

Product

Resources

About